Besins Healthcare is a pharmaceutical company specialising in the development of innovative drugs for the well-being of men and women throughout their life.
Gareth, aged 25
Patient profile is fictional and for illustrative purposes only.
Testicular cancer and its treatment put patients at risk of developing testosterone deficiency (TD).1,2
TD could have long term consequences for testicular cancer survivors.3-9
Symptoms of TD are not just limited to erectile dysfunction or low libido.1,2 Patients can also suffer from metabolic syndrome and poor cardiac health.5-7
It is thought that TD and chemotherapy are the main contributing factors in the development of metabolic syndrome in testicular cancer patients.8,9
Find out more about the signs and symptoms of TD here.
Long term follow-up of testicular cancer survivors is essential
91% of testicular cancer patients now survive for 10 years or longer,10,11 and the symptoms of TD can present themselves up to 20 years post treatment for testicular cancer, due to platinum-based chemotherapy.12
With high levels of testicular cancer survival, effective follow up monitoring should be a priority,10,11 especially as classic symptoms of TD may not always be mentioned by men.
TES/2020/009. April 2021.
Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: firstname.lastname@example.org